Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| May 18, 2026 | BlueCross BlueShield of Tennessee | Toripalimab-tpzi (Loqtorzi) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Loncastuximab Tesirine-lpyl (Zynlonta) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Linvoseltamab-gcpt (Lynozyfic) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Levoleucovorin (Fusilev), Levoleucovorin (Khapzory), Levoleucovorin | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Leuprolide Suspension (Lupron Depot, Leuprolide Acetate Depot)1-Month 3.75mg, 3-Month 11.25 mg) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Leuprolide Mesylate (Camcevi ETM; Camcevi Kit) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Leuprolide Acetate (Fensolvi) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Leuprolide Acetate Depot Suspension (Lupron Depot-Ped) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Laser Device for Obtaining Blood Sample | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Lanadelumab-flyo (Takhzyro) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Velmanase Alfa-tycv (Lamzede) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Pegloticase (Krystexxa) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Uveal Melanoma | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Pembrolizumab (Keytruda) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Sebelipase Alfa (Kanuma) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Mitomycin Gel(Jelmyto) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Irinotecan Liposome Injection (Onivyde) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Ipilimumab (Yervoy) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Inotersen (Tegsedi) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Inebilizumab-cdon (Uplizna) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | IncobotulinumtoxinA(Xeomin) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Talimogene Laherparepvec (Imlygic) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Tremelimumab-actl (Imjudo) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Tarlatamab-dlle (Imdelltra) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Nipocalimab-aahu (Imaavy) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Travoprost Intracameral Implant (iDose TR) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Ibalizumab-uiyk (Trogarzo) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Histrelin Acetate (Supprelin LA) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Guselkumab (Tremfya) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Golimumab (Simponi ARIA) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Givosiran (Givlaari) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Genetic Testing for Mitochondrial Disorders | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and Dissections, and Related Connective Tissue Disorders | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Gene Expression Profile Analysis for Prostate Cancer Management | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Gemtuzumab Ozogamicin (Mylotarg) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Gemcitabine (Inlexzo) intravesical system | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | DOCUMENTATION | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Fosdenopterin (Nulibry) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Fluocinolone Acetonide Implant (Yutiq) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Fluocinolone Acetonide Implant (Retisert) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Fluocinolone Acetonide Implant (Iluvien) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Icatibant (Firazyr), Icatibant (Sajazir), Icatibant | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Faricimab-svoa (Vabysmo) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Romosozumab-aqqg (Evenity) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Etranacogene Dezaparvovec-drlb (Hemgenix) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Eteplirsen (Exondys 51) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Eribulin Mesylate (Halaven) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Eptinezumab-jjmr (Vyepti) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Epoprostenol for Continuous Intravenous Infusion (Flolan/Veletri) | Criteria changed |